Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Recognizing and targeting the interconnectedness of diseases such as chronic kidney disease, heart failure, high cholesterol, type 2 diabetes in patients will help us to create more effective and holistic treatments, Barr said on the call
Therefore, additional information will be required to establish definitive conclusions
The medication cannot guarantee its effectiveness beyond 56 days at room temperature
A spokesperson for Eli Lilly, which produces Zepbound and Mounjaro, told The Independent that Zepbound and Mounjaro autoinjectors and Zepbound vials are approved for single-use onlydose-splitting or microdosing is not contemplated by the FDA-label and may pose patient safety risks. Novo Nordisk, which produces Ozempic and Wegovy, told The Independent the company "[does] not condone the misuse of our products." The company noted it is concerned about non-FDA approved knock-off versions of semaglutide and sources spreading misinformation about GLP-1s to the public. The FDA warns that using unapproved versions of GLP-1 drugs can be risky for patients. This story was updated on September 4, 2025 to include responses from Eli Lilly and Novo Nordisk Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments
Moreover, semaglutide treatment resulted in greater improvements in multiple secondary endpoints than placebo
Abrupt discontinuation can cause rebound appetite and metabolic changes
